A bat­tered Zaf­gen seeks strate­gic op­tions, proph­esy­ing on­go­ing study will un­like­ly lift FDA hold on di­a­betes drug

Zaf­gen, which back in 2015 crossed the $50 mark, is now firm­ly in pen­ny stock ter­ri­to­ry. Blight­ed by safe­ty con­cerns across a range of its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.